Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia

Aim. The present work aimed at studying the proatherogenic potential of doxorubicin-cyclophosphamide (AC) chemotherapy regimen while simultaneously substantiating the use of trimetazidine as a modifier of the changes induced.Material and Methods. The fundamental, randomized, controlled, experimental in vivo study was conducted. To perform the experimental work, 80 inbred Wistar rats were randomly divided into four groups with equal numbers of animals in each group. The course dosages doxorubicin, cyclophosphamide, and trimetazidine were 15, 150, and 42 mg/kg, respectively. The experiment lasted for 14 days. Trimetazidine was chosen as a probable stabilizer of endothelial functioning.Results. The deviations of the following parameters were evaluated in the framework of this study: total cholesterol, triglycerides, high-density lipoproteins, and low-density lipoproteins. Coronary index and atherogenic index (CA) were also analyzed as prognostic indicators. Statistically significant intergroup differences were recorded in lipid profiles (one-way ANOVA, p